Marginally low mass ratio close binary system V1191 Cyg

In this study, we present photometric and spectroscopic variations of the extremely small mass ratio ($q\simeq 0.1$) late-type contact binary system \astrobj{V1191 Cyg}. The parameters for the hot and cooler companions have been determined as $M_\textrm{h}$ = 0.13 (1) $M_{\odot}$, $M_\textrm{c}$ = 1.29 (8) $M_{\odot}$, $R_\textrm{h}$ = 0.52 (15) $R_{\odot}$, $R_\textrm{c}$ = 1.31 (18) $R_{\odot}$, $L_\textrm{h}$ = 0.46 (25) $L_{\odot}$, $L_\textrm{c}$ = 2.71 (80) $L_{\odot}$, the separation of the components is $a$= 2.20(8) $R_{\odot}$ and the distance of the system is estimated as 278(31) pc. Analyses of the times of minima indicates a period increase of $\frac{dP}{dt}=1.3(1)\times 10^{-6}$ days/yr that reveals a very high mass transfer rate of $\frac{dM}{dt}=2.0(4)\times 10^{-7}$$M_{\odot}$/yr from the less massive component to the more massive one. New observations show that the depths of the minima of the light curve have been interchanged.Comment: Accepted for publication in New Astronomy, 16 pages, 2 figures, 4 table

HS 2237+8154 : on the onset of mass transfer or entering the period gap?

We report follow-up observations of a new white dwarf/red dwarf binary HS 2237+8154, identified as a blue variable star from the Hamburg Quasar Survey. Ellipsoidal modulation observed in the R band as well as the radial velocity variations measured from time-resolved spectroscopy determine the orbital period to be Porb = 178.10 +- 0.08 min. The optical spectrum of HS 2237+8154 is well described by a combination of a Teff = 11500 +- 1500 K white dwarf (assuming log g = 8) and a dM 3.5 +- 0.5 secondary star. The distance implied from the flux scaling factors of both stellar components is d = 105 +- 25 pc. Combining the constraints obtained from the radial velocity of the secondary and from the ellipsoidal modulation, we derive a binary inclination of i = 50-70 and stellar masses of and Mwd = 0.47-0.67 M and Msec = 0.2-0.4 M. All observations imply that the secondary star must be nearly Roche-lobe filling. Consequently, HS 2237+8154 may be either a pre-cataclysmic variable close to the start of mass transfer, or - considering its orbital period - a cataclysmic variable that terminated mass transfer and entered the period gap, or a hibernating nova

Multi-wavelength spectrophotometry of EX Hydrae

We present phase-resolved infrared and optical spectrophotometry of the intermediate polar EX Hya supplemented by archival ultraviolet data. The spin-modulated emission from the accretion funnel and the emission from the accretion disk or ring contain substantial optically thin components. The white dwarf dominates the unmodulated flux in the ultraviolet and is identified by numerous absorption lines. Metal absorption in the accretion curtain may add to the observed spectral features. The secondary star is of spectral type M4+-1 and is detected by its ellipsoidal modulation. We derive a distance of 65+-11 pc which makes EX Hydrae one of the closest cataclysmic variables with a known distance. The luminosity derived from the integrated overall spectral energy distribution is 3x10^32 erg/s. The accretion rate of 3x10^15 g/s (for an 0.6 Msun white dwarf) is in reasonable agreement with the rates expected from angular momentum loss by gravitational radiation and from the observed spin-up of the white dwarfComment: 15 A&A Latex, 9 Figures, accepted for publication in A&

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours:a prospective, multicentre, non-inferiority trial

BACKGROUND: Patients with cancer have an increased risk of complications from SARS-CoV-2 infection. Vaccination to prevent COVID-19 is recommended, but data on the immunogenicity and safety of COVID-19 vaccines for patients with solid tumours receiving systemic cancer treatment are scarce. Therefore, we aimed to assess the impact of immunotherapy, chemotherapy, and chemoimmunotherapy on the immunogenicity and safety of the mRNA-1273 (Moderna Biotech, Madrid, Spain) COVID-19 vaccine as part of the Vaccination Against COVID in Cancer (VOICE) trial. METHODS: This prospective, multicentre, non-inferiority trial was done across three centres in the Netherlands. Individuals aged 18 years or older with a life expectancy of more than 12 months were enrolled into four cohorts: individuals without cancer (cohort A [control cohort]), and patients with solid tumours, regardless of stage and histology, treated with immunotherapy (cohort B), chemotherapy (cohort C), or chemoimmunotherapy (cohort D). Participants received two mRNA-1273 vaccinations of 100 μg in 0·5 mL intramuscularly, 28 days apart. The primary endpoint, analysed per protocol (excluding patients with a positive baseline sample [>10 binding antibody units (BAU)/mL], indicating previous SARS-CoV-2 infection), was defined as the SARS-CoV-2 spike S1-specific IgG serum antibody response (ie, SARS-CoV-2-binding antibody concentration of >10 BAU/mL) 28 days after the second vaccination. For the primary endpoint analysis, a non-inferiority design with a margin of 10% was used. We also assessed adverse events in all patients who received at least one vaccination, and recorded solicited adverse events in participants who received at least one vaccination but excluding those who already had seroconversion (>10 BAU/mL) at baseline. This study is ongoing and is registered with ClinicalTrials.gov, NCT04715438. FINDINGS: Between Feb 17 and March 12, 2021, 791 participants were enrolled and followed up for a median of 122 days (IQR 118 to 128). A SARS-CoV-2-binding antibody response was found in 240 (100%; 95% CI 98 to 100) of 240 evaluable participants in cohort A, 130 (99%; 96 to >99) of 131 evaluable patients in cohort B, 223 (97%; 94 to 99) of 229 evaluable patients in cohort C, and 143 (100%; 97 to 100) of 143 evaluable patients in cohort D. The SARS-CoV-2-binding antibody response in each patient cohort was non-inferior compared with cohort A. No new safety signals were observed. Grade 3 or worse serious adverse events occurred in no participants in cohort A, three (2%) of 137 patients in cohort B, six (2%) of 244 patients in cohort C, and one (1%) of 163 patients in cohort D, with four events (two of fever, and one each of diarrhoea and febrile neutropenia) potentially related to the vaccination. There were no vaccine-related deaths. INTERPRETATION: Most patients with cancer develop, while receiving chemotherapy, immunotherapy, or both for a solid tumour, an adequate antibody response to vaccination with the mRNA-1273 COVID-19 vaccine. The vaccine is also safe in these patients. The minority of patients with an inadequate response after two vaccinations might benefit from a third vaccination. FUNDING: ZonMw, The Netherlands Organisation for Health Research and Development

A Prominent Role for DC-SIGN+ Dendritic Cells in Initiation and Dissemination of Measles Virus Infection in Non-Human Primates

Measles virus (MV) is a highly contagious virus that is transmitted by aerosols. During systemic infection, CD150+T and B lymphocytes in blood and lymphoid tissues are the main cells infected by pathogenic MV. However, it is unclear which cell types are the primary targets for MV in the lungs and how the virus reaches the lymphoid tissues. In vitro studies have shown that dendritic cell (DC) C-type lectin DC-SIGN captures MV, leading to infection of DCs as well as transmission to lymphocytes. However, evidence of DC-SIGN-mediated transmission in vivo has not been established. Here we identified DC-SIGNhiDCs as first target cells in vivo and demonstrate that macaque DC-SIGN functions as an attachment receptor for MV. Notably, DC-SIGNhicells from macaque broncho-alveolar lavage and lymph nodes transmit MV to B lymphocytes, providing in vivo support for an important role for DCs in both initiation and dissemination of MV infection

The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation

Respiratory syncytial virus (RSV) is an important cause of acute respiratory disease in infants, immunocompromised subjects and the elderly. However, it is unclear why most primary RSV infections are associated with relatively mild symptoms, whereas some result in severe lower respiratory tract infections and bronchiolitis. Since RSV hospitalization has been associated with respiratory bacterial co-infections, we have tested if bacterial Toll-like receptor (TLR) agonists influence RSVA2- GFP infection in human primary cells or cell lines. The synthetic bacterial lipopeptide Pam3-Cys-Ser-Lys4 (Pam3CSK4), the prototype ligand for the heterodimeric TLR1/TLR2 complex, enhanced RSV infection in primary epithelial, myeloid and lymphoid cells. Surprisingly, enhancement was optimal when lipopeptides and virus were added simultaneously, whereas addition of Pam3CSK4 immediately after infection had no effect. We have identified two structurally related lipopeptides without TLR-signaling capacity that also modulate RSV infection, whereas Pam3CSK4-reminiscent TLR1/2 agonists did not, and conclude that modulation of infection is independent of TLR activation. A similar TLR-independent enhancement of infection could also be demonstrated for wild-type RSV strains, and for HIV-1, measles virus and human metapneumovirus. We show that the effect of Pam3CSK4 is primarily mediated by enhanced binding of RSV to its target cells. The Npalmitoylated cystein

Analyseresultaten Zevenlanden-studie

In het kader van de Zevenlandenstudie, een epidemiologische studie naar de relatie tussen voeding en kanker, heeft het RIKILT de gemiddelde voedingspakketten van 16 cohorten onderzocht op het gehalte aan vitamines, spoorelementen en non-nutritieve stoffen als glucosinolaten en flavonoïden. In dit verslag worden de analytisch-chemische aspecten van dit onderzoek nader toegelicht, waarbij aandacht wordt besteed aan de gebruikte analysemethoden, de monstervoorbehandeling, de monsterbewaring en de kwaliteitsbewaking van de analyses